The PD-1 and PD-L1 pathways are rather important for the immune checkpoint inhibitors, as most cancer cells express PD-L1 as cell surface receptors, which play a major role in regulating T-cell exhaustion by binding onto PD-1 [46]. Here, CD177 is linked to cancer.